Outcomes4Me
Oncology Clinical Trial Finder
Breast Cancer
Location

Recruiting • Phase NA • Stage 0, I, II, III, IV • ER negative • PR negative • HER2 negative • Post-Menopausal • Interventional

The following is imported from ClinicalTrials.gov:

Abbreviate or FAST Breast MRI for Supplemental Breast Cancer Screening for Black Women at Average Risk and Dense Breasts

500 patients will be prospectively recruited to undergo a fast breast MRI examination. The women will be recruited for the study will meet the following criteria: 1. African American 2. negative DBT examination 11 months prior to recruitment 3. Heterogeneously and Extremely breast densities 4. clinically asymptomatic- no palpable masses, focal thickening or clinically significant discharge. Investigators will identify these patients EPIC database utilizing the date of their last mammogram. Interested patients may contact our research coordinators by the phone number provided in the recruitment materials. The study recruitment information will also be shared with referring physicians. Physicians may also directly refer patients to the study.

500 patients will be prospectively recruited to undergo an abbreviated or "FAST" breast MRI examination. The women will be recruited for the study must meet the following criteria: 1. African American 2. negative DBT examination no more than 11 months prior to the FAST MR 3. Heterogeneously and Extremely breast densities as graded on their most recent mammogram 4. clinically asymptomatic- no palpable masses, focal thickening or clinically significant nipple discharge. Investigators will identify these women via the EPIC database utilizing the date of their last mammogram. Interested women may contact our research coordinators by the phone number provided in the recruitment materials. The study recruitment information will also be shared with referring physicians. Physicians may also directly refer patients to the study.

Breast Cancer

Study Design
Study type:

Observational

Estimated enrollment:

500 participant

Actual study start date:

September 23, 2021

Eligibility Criteria
Ages eligible for study:

40 - 75

Sexes eligible for study:

female


Arms and Intervention
  • Fast Breast Abbreviated Magnetic Renounce Imaging

Inclusion criteria
  • african american female

  • negative dbt examination within eleven months prior to recruitment

  • heterogeneoulsy and extremely breast densities

  • clinically asymptomatic- no palpable masses or focal thickening, etc.

Exclusion criteria
  • patients who are pregnant and lactating

  • patient who have not had a mammogram (dbt) in the past 11months

  • patients who are unwilling or unable to provide written informed consent

  • patients symptomatic for breast disease (e.g. experiencing discharge, lumps, ect.)

  • recent breast surgery in the past 2 years including breast enhancements (e.g. implants or injections)

  • patients who are unable to received an mri with gadolinium contrast

  • patients who have not had an mri of the breast with the past year

Trial Information at Site
Last Updated:
Trial Information
ClinicalTrial.gov ID:

Recruiting

Estimated Enrollment:

500

Last Updated:

07/21/2023


Site Contact

Jessica Nunez

Jessica.Nunez@pennmedicine.upenn.edu

215-746-6788

UPENN

Philadelphia, Pennsylvania, United States, 19104


Trial Contact

Jessica Nunez

Jessica.Nunez@pennmedicine.upenn.edu

215-746-6788


Isabella Strickler

Isabella.Strickler@pennmedicine.upenn.edu

313-600-3369


Principal Investigator

Emily F Conant, MD


Trial Sponsor

Abramson Cancer Center at Penn Medicine

Study Location (1)

UPENN

Philadelphia, Pennsylvania, United States

Outcomes4Me

© 2024 Outcomes4Me Inc. All rights reserved.